Data analytics company InMed AI has received US Food and Drug Administration (FDA) 510(k) clearance for NeuroShield, an artificial intelligence (AI) powered tool that uses 3D MR images to automatically quantify brain volumes.
The platform supports neurologists and neuroradiologists in diagnosing and treating neurodegenerative diseases such as dementia and Alzheimer’s disease (AD).
InMed founder Latha Poonamallee said: “As a team, we continue to move forward propelled by our mission to bring affordable, accessible, reliable, and state-of-the-art healthcare tools to everyone everywhere. We believe that investing in healthcare is investing in our collective human future and that technology is a great lever to move towards precision health to extend quality of life.”
A report from GlobalData’s Medical Intelligence Centre highlights that an AI-based app or platform could make a huge difference in the treatment of AD and dementia. They could help make diagnosis more accessible for patients while also relieving some of the workload from healthcare professionals.
According to the Global Burden of Disease Study 2019, dementia is estimated to almost triple, from 57.4 million cases in 2019 to 153.8 million cases by 2050.
In August 2023, South Korean company Lotte Healthcare partnered with iMediSync to develop an AI-based healthcare service. The two companies plan to create mobile health diagnostic tools using AI with a focus on senior care, and those with neuropsychiatric disorders such as AD.
According to InMed AI, NeuroShield is the first device of its kind to provide reference ranges that can be adjusted to age, gender, and ethnicity, contributing to more inclusive healthcare devices.
“We will continue to be attentive to populations that are traditionally underserved and underrepresented both in the global north and south markets," said Poonamallee.
